

Supporting Information

Highly Enantioselective Ir/f-amphox-Catalyzed Hydrogenation of Ketoamides: Efficient Access to Chiral Hydroxy Amides

Yang Hu,^a Xuguang Yin,^a Ziyi Chen,^a Xiu-Qin Dong^{*a} and Xumu Zhang^{*a,b}

^a Key Laboratory of Biomedical Polymers, Ministry of Education, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei, 430072, P. R. China.

^b Department of Chemistry, Southern University of Science and Technology, Shenzhen, 518000, P. R. China.

Contents


1. General remarks.....	2
2. General procedure for the preparation of substrate compounds.....	2
3. Asymmetric hydrogenation of ketoamides.....	10
4. NMR spectra of substrate compounds.....	18
5. NMR spectra of products.....	33
6. HPLC spectra.....	48
7. Reference	78

1. General remarks

All reactions and manipulations which are sensitive to moisture or air were performed in an argon-filled glovebox or using standard Schlenk techniques. Hydrogen gas (99.999%) was purchased from Shanghai Regulator Factory Co., Ltd. Anhydrous *i*-PrOH, EtOH, MeOH, DCM, EtOAc, toluene and CHCl₃ were purchased from J&K. Anhydrous THF, 1,4-dioxane was distilled from sodium benzophenone ketyl. Anhydrous ClCH₂CH₂Cl were freshly distilled from calcium hydride. K₂CO₃, Cs₂CO₃, KOH, MeOK, *t*-BuONa and *t*-BuOK were purchased from J&K. [Ir(COD)Cl]₂ was prepared according to the literature.¹⁻² ¹H, ¹³C and ³¹P NMR spectra were recorded with a Bruker ADVANCE III (400 MHz) spectrometer with CDCl₃ as the solvent and tetramethylsilane (TMS) as the internal standard. Chemical shifts are reported in parts per million (ppm, δ scale) downfield from TMS at 0.00 ppm and referenced to the CDCl₃ at 7.26 ppm (for ¹H NMR) or 77.0 ppm (for ¹³C NMR). Data are reported as: multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant in hertz (Hz) and signal area integration in natural numbers. ¹³C NMR and ³¹P NMR analyses were run with decoupling. Optical rotations [α]_D were determined using a PERKIN ELMER polarimeter 343 instrument. HPLC analyses were performed using Daicel chiral column. A single crystal of (*R*)-**2i** was grown from its solution in ethyl acetate, which is suitable for X-ray diffraction analysis. The structure showed that the absolute configuration of **2i** is (*R*). The absolute configuration of other hydrogenation products were assigned by analogy. The absolute configuration of products **2m** and **2n** were assigned by the comparison of optical rotation datas according to literature.³⁻⁴

2. General procedure for the preparation of substrate compounds

Scheme S1. General procedure for the preparation of substrates route 1.⁵⁻⁶




Step 1:

Under a nitrogen atmosphere, a mixture of anhydrous aluminum chloride (8.0 g, 60 mmol) in anhydrous dichloromethane (50 mL) was stirred and cooled to -10 °C. A solution of glutaric anhydride (4.8 g, 42 mmol) and substituted benzene (**SM-1**, 40 mmol) was added dropwise to the cooled mixture with stirring. After 5h at -10 °C, the reaction mixture was poured into ice-cooled 3.5 M HCl (100 mL), and the product was extracted into dichloromethane. The extract was washed with cold saturated aqueous sodium carbonate, and the aqueous layers were acidified and extracted with dichloromethane. The extract was washed with brine, dried over anhydrous sodium sulfate and evaporated in vacuo without further purification to give **SM-2** as white crystal.

Step 2:


SM-2 (20 mmol) and aniline (1.95 g, 21 mmol) were resolved in 100 mL dry dichloromethane and cooled in ice-water bath protected by N₂ flushed, then 1-ethy-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC HCl) (4.01 g, 21 mmol) and 4-dimethylaminopyridine (4-DMAP) (0.244 g, 2 mmol) were added; Ice-water bath was removed after adding. The mixture was stirred overnight. Wash the mixture with 1% HCl aqueous solution (x 3), saturated brine (x 1), 1 M NaHCO₃ (x 3) and saturated brine (x 1) respectively. The crude product was chromatographed on silica gel by 0-10% Ethyl acetate (EA) in DCM as eluent.

5-oxo-N,5-diphenylpentanamide (**1a**)




¹H NMR (400 MHz, Chloroform-*d*) δ 8.02 (d, *J* = 7.5 Hz, 2H), 7.62 (t, *J* = 7.4 Hz, 1H), 7.57 (d, *J* = 7.7 Hz, 3H), 7.51 (t, *J* = 7.7 Hz, 2H), 7.36 (t, *J* = 7.8 Hz, 2H), 7.14 (t, *J* = 7.4 Hz, 1H), 3.18 (t, *J* = 6.7 Hz, 2H), 2.53 (t, *J* = 7.1 Hz, 2H), 2.25-2.20 (m, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 200.26, 170.99, 137.99, 136.63, 133.33, 129.01, 128.70, 128.14, 124.22, 119.84, 37.31, 36.49, 20.13.

5-oxo-N-phenyl-5-(p-tolyl)pentanamide (**1d**)




^1H NMR (400 MHz, Chloroform-*d*) δ 7.88 (d, J = 8.2 Hz, 2H), 7.58 (s, 1H), 7.53 (d, J = 7.8 Hz, 2H), 7.32 (t, J = 7.9 Hz, 2H), 7.27-7.25 (m, 2H), 7.10 (t, J = 7.4 Hz, 1H), 3.10 (t, J = 6.7 Hz, 2H), 2.47 (t, J = 7.1 Hz, 2H), 2.41 (s, 3H), 2.21-2.14 (m, 2H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 199.94, 170.92, 144.18, 137.96, 134.17, 129.38, 129.01, 128.28, 124.20, 119.76, 37.11, 36.60, 21.70, 20.28.

5-(4-methoxyphenyl)-5-oxo-N-phenylpentanamide (1g)




^1H NMR (400 MHz, Chloroform-*d*) δ 7.96 (d, J = 8.9 Hz, 2H), 7.62 (s, 1H), 7.54 (d, J = 7.8 Hz, 2H), 7.32 (t, J = 7.9 Hz, 2H), 7.10 (t, J = 7.4 Hz, 1H), 6.93 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H), 3.08 (t, J = 6.7 Hz, 2H), 2.47 (t, J = 7.1 Hz, 2H), 2.20-2.13 (m, 2H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 198.89, 170.98, 163.65, 138.00, 130.48, 129.72, 129.01, 124.18, 119.76, 113.82, 55.53, 36.86, 36.62, 20.45.

5-(4-fluorophenyl)-5-oxo-N-phenylpentanamide (1h)



^1H NMR (400 MHz, Chloroform-*d*) δ 8.09-7.91 (m, 2H), 7.56-7.52 (m, 3H), 7.32 (t, J = 7.9 Hz, 2H), 7.13 (t, J = 8.7 Hz, 3H), 3.10 (t, J = 6.8 Hz, 2H), 2.49 (t, J = 7.1 Hz, 2H), 2.20-2.13 (m, 2H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 198.57, 170.87, 165.85 (d, J = 255.1 Hz), 137.91, 133.07 (d, J = 3.0 Hz), 130.80 (d, J = 9.4 Hz), 129.03, 124.29, 119.82, 115.79 (d, J = 21.9 Hz), 37.24, 36.38, 20.06.


5-(4-chlorophenyl)-5-oxo-N-phenylpentanamide (1i)



^1H NMR (400 MHz, Chloroform-*d*) δ 7.92 (d, J = 8.6 Hz, 2H), 7.52 (d, J = 7.8 Hz, 2H), 7.44 (d, J = 8.6 Hz, 3H), 7.32 (t, J = 7.9 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H),


3.11 (t, $J = 6.8$ Hz, 2H), 2.49 (t, $J = 7.0$ Hz, 2H), 2.20-2.14 (m, 2H). ^{13}C NMR (100 MHz, Chloroform- d) δ 198.90, 170.75, 139.74, 137.86, 134.95, 129.56, 129.04, 129.01, 124.30, 119.78, 37.28, 36.35, 19.97.

5-oxo-N-phenyl-5-(thiophen-2-yl)pentanamide (1k)




^1H NMR (400 MHz, Chloroform- d) δ 7.75 (d, $J = 3.2$ Hz, 1H), 7.65 (d, $J = 4.9$ Hz, 1H), 7.58 (s, 1H), 7.53 (d, $J = 7.8$ Hz, 2H), 7.32 (t, $J = 7.9$ Hz, 2H), 7.16-7.08 (m, 3H), 3.07 (t, $J = 6.8$ Hz, 2H), 2.49 (t, $J = 7.1$ Hz, 2H), 2.22-2.15 (m, 2H). ^{13}C NMR (100 MHz, Chloroform- d) δ 193.35, 170.91, 143.99, 138.01, 134.02, 132.46, 128.99, 128.33, 124.21, 119.86, 37.93, 36.32, 20.55.

4-oxo-N,4-diphenylbutanamide (1o)



^1H NMR (400 MHz, Chloroform- d) δ 8.00 (d, $J = 7.2$ Hz, 2H), 7.84 (s, 1H), 7.58 (t, $J = 7.4$ Hz, 1H), 7.52 (d, $J = 7.9$ Hz, 2H), 7.47 (t, $J = 7.6$ Hz, 2H), 7.30 (t, $J = 7.9$ Hz, 2H), 7.08 (t, $J = 7.4$ Hz, 1H), 3.46 (t, $J = 6.4$ Hz, 2H), 2.82 (t, $J = 6.4$ Hz, 2H). ^{13}C NMR (100 MHz, Chloroform- d) δ 199.34, 170.52, 138.02, 136.36, 133.51, 128.96, 128.71, 128.16, 124.14, 119.78, 34.12, 31.40.

Scheme S2. General procedure for the preparation of substrates route 2. ⁶⁻⁷



Step 1:

1) A three-necked round bottom flask equipped with condenser was flame dried and cooled to room temperature. Into this flask was placed (1.46 g, 60 mmol) magnesium turnings, anhydrous THF (40 mL) and a chip of iodine. The mixture was heated to 70 °C, then started to add the anhydrous THF solution of substituted bromophenyl (**SM-3**, 20 mmol) dropwise. When the solution in the flask started to


bubble and the colour of iodine started to fade, the flask was moved out of the oil bath and kept dropping. The mixture was heated to 70 °C and kept 2h. The solution was then cooled to room temperature and used directly.

2) To the solution of glutaric anhydride (2.4 g, 21 mmol) in THF under a N₂ atmosphere **SM-4** was added dropwise the corresponding Grignard reagent at 0 °C. The solution was warmed to room temperature and stirred for a further 3 hours. The reaction was quenched with 10% HCl, and THF was removed under vacuum. The resulting aqueous solution was extracted with DCM. The combined organic layers were washed with brine, dried (Na₂SO₄) and evaporated under vacuum to give a white solid as a crude product **SM-4**.

Step 2:


SM-4 (20 mmol) and aniline (1.95 g, 21 mmol) were resolved in 100 mL dry dichloromethane and cooled in ice-water bath protected by N₂ flushed, then 1-ethy-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC HCl) (4.01 g, 21 mmol) and 4-dimethylaminopyridine (4-DMAP) (0.244 g, 2 mmol) were added; Ice-water bath was removed after adding. The mixture was stirred overnight. Wash the mixture with 1% HCl aqueous solution (x 3), saturated brine (x 1), 1 M NaHCO₃ (x 3) and saturated brine (x 1) respectively. The crude product was chromatographed on silica gel by 0-10% Ethyl acetate (EA) in DCM as eluent.

5-oxo-N-phenyl-5-(o-tolyl)pentanamide (1b)




¹H NMR (400 MHz, Chloroform-*d*) δ 7.66 (d, *J* = 7.5 Hz, 1H), 7.64 (s, 1H), 7.53 (d, *J* = 7.8 Hz, 2H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.31 (t, *J* = 7.9 Hz, 2H), 7.25 (t, *J* = 6.9 Hz, 2H), 7.10 (t, *J* = 7.4 Hz, 1H), 3.04 (t, *J* = 6.8 Hz, 2H), 2.50 (s, 3H), 2.47 (t, *J* = 7.2 Hz, 2H), 2.18-2.11 (m, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 204.20, 170.91, 138.19, 137.94, 137.55, 132.08, 131.55, 129.02, 128.70, 125.83, 124.24, 119.81, 40.11, 36.59, 21.50, 20.28.

5-oxo-N-phenyl-5-(m-tolyl)pentanamide (1c)




^1H NMR (400 MHz, Chloroform-*d*) δ 7.78 (s, 1H), 7.76 (s, 1H), 7.53 (d, J = 7.8 Hz, 3H), 7.41-7.29 (m, 4H), 7.10 (t, J = 7.4 Hz, 1H), 3.12 (t, J = 6.7 Hz, 2H), 2.48 (t, J = 7.1 Hz, 2H), 2.41 (s, 3H), 2.21-2.14 (m, 2H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 200.49, 170.92, 138.51, 137.96, 136.68, 134.10, 129.02, 128.66, 128.58, 125.37, 124.21, 119.77, 37.28, 36.55, 21.39, 20.19.

5-(2-methoxyphenyl)-5-oxo-N-phenylpentanamide (1e)




^1H NMR (400 MHz, Chloroform-*d*) δ 7.70 (d, J = 7.7 Hz, 1H), 7.54 (d, J = 7.8 Hz, 2H), 7.47 (t, J = 7.8 Hz, 1H), 7.31 (t, J = 7.9 Hz, 2H), 7.09 (t, J = 7.4 Hz, 1H), 7.00 (dd, J = 11.0, 4.0 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 3.87 (s, 3H), 3.12 (t, J = 6.7 Hz, 2H), 2.45 (t, J = 7.3 Hz, 2H), 2.17-2.10 (m, 2H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 202.66, 171.22, 158.69, 138.09, 133.76, 130.27, 128.98, 128.00, 124.09, 120.68, 119.72, 111.61, 55.53, 42.38, 36.88, 20.40.

5-(3-methoxyphenyl)-5-oxo-N-phenylpentanamide (1f)



^1H NMR (400 MHz, Chloroform-*d*) δ 7.57-7.48 (m, 5H), 7.37 (t, J = 7.9 Hz, 1H), 7.32 (t, J = 7.9 Hz, 2H), 7.14 – 7.08 (m, 2H), 3.85 (s, 3H), 3.12 (t, J = 6.7 Hz, 2H), 2.48 (t, J = 7.1 Hz, 2H), 2.21-2.14 (m, J = 6.9 Hz, 2H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 200.07, 170.94, 159.86, 138.00, 137.98, 129.71, 129.01, 124.22, 120.83, 119.81, 119.78, 112.26, 55.46, 37.42, 36.47, 20.19.


5-(naphthalen-2-yl)-5-oxo-N-phenylpentanamide (1j)



^1H NMR (400 MHz, Chloroform-*d*) δ 8.50 (s, 1H), 8.04 (d, J = 8.6 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.88 (t, J = 8.2 Hz, 2H), 7.61 (t, J = 6.9 Hz, 1H), 7.55 (t, J = 6.9


Hz, 4H), 7.32 (t, $J = 7.9$ Hz, 2H), 7.10 (t, $J = 7.4$ Hz, 1H), 3.28 (q, $J = 6.7$ Hz, 2H), 2.53 (t, $J = 7.1$ Hz, 2H), 2.28-2.21 (m, 2H). ^{13}C NMR (100 MHz, Chloroform- d) δ 200.17, 170.89, 137.94, 135.67, 133.97, 132.52, 130.00, 129.65, 129.04, 128.61, 128.57, 127.80, 126.87, 124.25, 123.75, 119.76, 37.28, 36.57, 20.30

5-cyclohexyl-5-hydroxy-N-phenylpentanamide (1l)



^1H NMR (400 MHz, Chloroform- d) δ 7.58 (s, 1H), 7.52 (d, $J = 7.8$ Hz, 2H), 7.31 (t, $J = 7.9$ Hz, 2H), 7.10 (t, $J = 7.4$ Hz, 1H), 2.59 (t, $J = 6.8$ Hz, 2H), 2.37 (t, $J = 7.2$ Hz, 2H), 2.03-1.95 (m, 2H), 1.87-1.74 (m, 5H), 1.44-1.11 (m, 6H). ^{13}C NMR (100 MHz, Chloroform- d) δ 214.43, 170.91, 137.95, 129.01, 124.19, 119.73, 50.89, 39.21, 36.58, 33.97, 28.50, 25.81, 25.63, 24.96, 19.61.

Scheme S3. General procedure for the preparation of substrates route 3.^{6, 8}



Step 1:


A mixture of acetophenone **SM-5** (4.8 g, 40 mmol) and selenium dioxide (6.7 g, 60 mmol) in dry pyridine (20 mL) was stirred at 100 °C under nitrogen atmosphere for 15 h and then cooled in an ice bath. After the disappearance of acetophenone **SM-5** detected by TLC, the mixture was filtrated and removing the organic solvent by evaporation. Then 2 M sodium hydroxide solution was added to the residue and some ethyl acetate followed. Subsequently 36–38% concentrated hydrochloric acid was put into the mixture dropwise and α -keto acid **SM-6** was separated out as a pale yellow oil in 78% yield.

Step 2:

SM-6 (20 mmol) and aniline (1.94 g, 21 mmol) were resolved in 100 mL dry dichloromethane and cooled in ice-water bath protected by N_2 flushed, then 1-ethy-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC HCl) (4.01 g, 21 mmol)


and 4-dimethylaminopyridine (4-DMAP) (0.244 g, 2 mmol) were added; Ice-water bath was removed after adding. The mixture was stirred overnight. Wash the mixture with 1% HCl aqueous solution (x 3), saturated brine (x 1), 1 M NaHCO₃ (x 3) and saturated brine (x 1) respectively. The crude product was chromatographed on silica gel by 0-10% Ethyl acetate (EA) in DCM as eluent.

2-oxo-N,2-diphenylacetamide (1m)



¹H NMR (400 MHz, Chloroform-*d*) δ 8.95 (s, 1H), 8.42 (d, *J* = 7.2 Hz, 2H), 7.71 (d, *J* = 7.7 Hz, 2H), 7.66 (d, *J* = 7.4 Hz, 1H), 7.52 (t, *J* = 7.8 Hz, 2H), 7.41 (t, *J* = 8.0 Hz, 2H), 7.21 (t, *J* = 7.4 Hz, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 187.46, 158.88, 136.64, 134.70, 133.08, 131.51, 129.28, 128.61, 125.35, 119.95.

Scheme S4. General procedure for the preparation of substrates route 4.^{6,9}



Step 1:


A 250 mL round-bottom flask was equipped with a magnetic stir bar and charged with ethyl 3-oxo-3-phenylpropanoate **SM-7** (80 mmol, 14 mL) and 80 mL NaOH (1 M) solution. After stirring overnight, the solution was poured into a separatory funnel and washed four times with 10 mL of DCM each. The aqueous layer was cooled in an ice bath and a 3 M solution of HCl was added until the solution was around pH $\approx$ 1. The 3-oxo-3-phenylpropanoic acid **SM-8** was obtained, which was used immediately without further purification. White solid, 62% yield (8.0 g).

Step 2:

SM-8 (20 mmol) and aniline (1.94 g, 21 mmol) were resolved in 100 mL dry dichloromethane and cooled in ice-water bath protected by N₂ flushed, then 1-ethy-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC HCl) (4.01 g, 21 mmol) and 4-dimethylaminopyridine (4-DMAP) (0.244 g, 2 mmol) were added; Ice-water bath was removed after adding. The mixture was stirred overnight. Wash the mixture


with 1% HCl aqueous solution (x 3), saturated brine (x 1), 1 M NaHCO₃ (x 3) and saturated brine (x 1) respectively. The crude product was chromatographed on silica gel by 0-10% Ethyl acetate (EA) in DCM as eluent.

3-oxo-N,3-diphenylpropanamide (1n)




¹H NMR (400 MHz, Chloroform-*d*) δ 9.32 (s, 1H), 8.05 (d, *J* = 7.3 Hz, 2H), 7.65 (t, *J* = 7.4 Hz, 1H), 7.59 (d, *J* = 7.7 Hz, 2H), 7.53 (t, *J* = 7.7 Hz, 2H), 7.34 (t, *J* = 7.9 Hz, 2H), 7.13 (t, *J* = 7.4 Hz, 1H), 4.13 (s, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 196.49, 163.90, 137.57, 136.02, 134.42, 129.03, 129.01, 128.64, 124.61, 120.22, 45.55.

3. Asymmetric hydrogenation of ketoamides




General procedure (S/C = 10 000): To a 4.0 mL vial was added the catalyst precursor [Ir(COD)Cl]₂ (1.4 mg, 2.0 × 10⁻³ mmol), ligand **L5** (2.4 mg, 4.2 × 10⁻³ mmol) and anhydrous *i*PrOH (2.0 mL) in the argon-filled glovebox. The mixture was stirred for 2.0 h at room temperature giving orange red solution. And then 0.2 mmol ketoamides, KOH (4 mol%) were added into a 5 mL hydrogenation vessel. 1.0 mL anhydrous *i*PrOH was added as solvent and a solution of Ir/f-amphox **L5** in anhydrous *i*PrOH (10.0 μL) was added via an injection port. Then the vessel was placed in an autoclave, closed it and moved it out from glovebox. The autoclave quickly purged with hydrogen gas for three times, then pressurized to 40 atm H₂. The reaction solution was stirred at room temperature until for 12 h, then released pressure carefully. The solution of reaction mixture was purified by a flash chromatography on a silical gel with ethyl acetate and the solvent was removed under reduced pressure. The ee value was determined by chiral HPLC analysis of the chiral amino alcohol directly.

Asymmetric hydrogenation of 5-(4-fluorophenyl)-5-oxo-N-phenylpentanamide (1h) at S/C = 50 000:




To a 4.0 mL vial was added the catalyst precursor $[\text{Ir}(\text{COD})\text{Cl}]_2$ (1.4 mg, 2.0×10^{-3} mmol), ligand f-amphox **L5** (2.4 mg, 4.2×10^{-3} mmol) and anhydrous *i*PrOH (2.0 mL) in the argon-filled glovebox. The mixture was stirred for 2.0 h at 25 °C giving orange red solution. 5-(4-fluorophenyl)-5-oxo-N-phenylpentanamide (**1h**) (1 mmol, 286 mg) and KOH (0.02 mmol, 1.1 mg) were added into a 5 mL hydrogenation vessel. 1.0 mL anhydrous *i*PrOH was added as solvent and a solution of Ir/f-amphox **L5** in anhydrous *i*PrOH (10 μL , 2.0×10^{-3} mol/L) was added via an injection port. Then the vessel was placed in an autoclave, closed it and moved it out from glovebox. The autoclave was quickly purged with hydrogen gas for three times, then pressurized to 80 atm H_2 . The reaction solution was stirred at room temperature (25 °C–30 °C) until for 36 h, then released pressure carefully. The solvent of the reaction mixture was removed under reduced pressure and the residue was purified by a flash chromatography on a silical gel with ethyl acetate as eluent to afford the chiral (*R*)-5-(4-fluorophenyl)-5-hydroxy-N-phenylpentanamide (**2h**), >99% conversion, >99% ee.

(*R*)-5-hydroxy-N,5-diphenylpentanamide (2a)




White solid, $[\alpha]_{\text{D}}^{20} = 25.7$ ($c = 1.0$, CHCl_3), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel AD-H column, 220 nm, 20 °C, *n*-hexane: *i*-PrOH = 85:15; flow 1.0 mL/min; t_{R} (major) = 13.9 min, t_{R} (minor) = 12.3 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.53 (s, 1H), 7.49 (d, $J = 7.9$ Hz, 2H), 7.33 (d, $J = 4.4$ Hz, 4H), 7.32–7.26 (m, 3H), 7.09 (t, $J = 7.4$ Hz, 1H), 4.72 (s, 1H), 2.55 (d, $J = 2.2$ Hz, 1H), 2.39 (t, $J = 6.7$ Hz, 2H), 1.91–1.75 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.31, 144.52, 137.88, 129.02, 128.56, 127.66, 125.80, 124.25, 119.79, 74.33, 38.14, 37.26, 21.91.

(*R*)-5-hydroxy-N-phenyl-5-(*o*-tolyl)pentanamide (2b)




White solid, $[\alpha]_D^{20} = 39.4$ ($c = 1.0$, CHCl_3), >99% conversion, 95% ee. The enantiomeric excess was determined by HPLC on Chiracel AD-H column, 220 nm, 20 °C, *n*-hexane: *i*-PrOH = 90:10; flow 1.0 mL/min; t_R (major) = 21.2 min, t_R (minor) = 22.5 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.52-7.46 (m, 4H), 7.31 (t, $J = 7.9$ Hz, 2H), 7.23 (t, $J = 7.4$ Hz, 1H), 7.17 (t, $J = 6.6$ Hz, 1H), 7.14-7.08 (m, 2H), 5.00 (s, 1H), 2.46-2.42 (m, 2H), 2.33 (s, 3H), 2.24 (s, 1H), 2.00-1.76 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.28, 142.68, 137.89, 134.27, 130.47, 129.03, 127.31, 126.38, 125.06, 124.25, 119.77, 70.60, 37.30, 36.94, 22.21, 19.10.

(*R*)-5-hydroxy-N-phenyl-5-(*m*-tolyl)pentanamide (2c)



White solid, $[\alpha]_D^{20} = 16.3$ ($c = 1.0$, CHCl_3), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel AD-H column, 220 nm, 20 °C, *n*-hexane: *i*-PrOH = 85:15; flow 1.0 mL/min; t_R (major) = 13.8 min, t_R (minor) = 10.7 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.52 (s, 1H), 7.49 (d, $J = 7.8$ Hz, 2H), 7.30 (t, $J = 7.9$ Hz, 2H), 7.22 (t, $J = 7.5$ Hz, 1H), 7.17-7.05 (m, 4H), 4.69 (s, 1H), 2.46 (s, 1H), 2.40 (t, $J = 6.8$ Hz, 2H), 2.34 (s, 3H), 1.87-1.75 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.39, 144.47, 138.17, 137.89, 128.96, 128.40, 128.34, 126.46, 124.19, 122.81, 119.78, 74.29, 38.09, 37.22, 21.96, 21.46.


(*R*)-5-hydroxy-N-phenyl-5-(*p*-tolyl)pentanamide (2d)



White solid, $[\alpha]_D^{20} = 19.9$ ($c = 1.0$, CHCl_3), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel AS-H column, 220 nm, 20 °C, *n*-hexane: *i*-PrOH = 90:10; flow 1.0 mL/min; t_R (major) = 20.1 min, t_R (minor) = 22.4 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.53 (s, 1H), 7.42 (d, $J = 7.8$ Hz, 2H), 7.22 (t, $J = 7.9$ Hz, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 7.06 (d, $J = 7.9$ Hz, 2H), 7.01 (t, $J = 7.4$ Hz, 1H), 4.61 (t, $J = 5.8$ Hz, 1H), 2.47 (s, 1H), 2.31 (t, $J = 6.5$ Hz, 2H), 2.26 (s,


3H), 1.85-1.61 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.42, 141.49, 137.88, 137.25, 129.15, 128.92, 125.70, 124.15, 119.78, 74.09, 38.02, 37.19, 21.95, 21.08.

(*R*)-5-hydroxy-5-(2-methoxyphenyl)-*N*-phenylpentanamide (2e)




White solid, $[\alpha]_{\text{D}}^{20} = 17.9$ ($c = 2.5$, CHCl_3), >99% conversion, 88% ee. The enantiomeric excess was determined by HPLC on Chiracel AD-H column, 220 nm, 20°C, *n*-hexane: *i*-PrOH = 90:10; flow 1.0 mL/min; t_{R} (minor) = 44.2 min, t_{R} (major) = 56.1 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.64 (s, 1H), 7.50 (d, $J = 7.8$ Hz, 2H), 7.36-7.27 (m, 3H), 7.24-7.22 (m, 1H), 7.08 (t, $J = 7.4$ Hz, 1H), 6.95 (t, $J = 7.5$ Hz, 1H), 6.86 (d, $J = 8.1$ Hz, 1H), 4.95 (d, $J = 4.9$ Hz, 1H), 3.82 (s, 3H), 2.92 (d, $J = 5.5$ Hz, 1H), 2.44-2.40 (m, 2H), 1.92-1.80 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.56, 156.36, 138.05, 132.21, 128.97, 128.43, 126.76, 124.13, 120.84, 119.81, 110.51, 70.40, 55.31, 37.38, 36.15, 22.36.

(*R*)-5-hydroxy-5-(3-methoxyphenyl)-*N*-phenylpentanamide(2f)




White solid, $[\alpha]_{\text{D}}^{20} = 20.1$ ($c = 1.0$, CHCl_3), >99% conversion, 98% ee. The enantiomeric excess was determined by HPLC on Chiracel AD-H column, 220 nm, 20°C, *n*-hexane: *i*-PrOH = 90:10; flow 1.0 mL/min; t_{R} (major) = 43.4 min, t_{R} (minor) = 35.1 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.60 (s, 1H), 7.49 (d, $J = 7.9$ Hz, 2H), 7.29 (t, $J = 7.9$ Hz, 2H), 7.23 (d, $J = 8.1$ Hz, 1H), 7.08 (t, $J = 7.4$ Hz, 1H), 6.95-6.85 (m, 2H), 6.81-6.79 (m, 1H), 4.69 (s, 1H), 3.78 (s, 3H), 2.70 (s, 1H), 2.38 (t, $J = 6.7$ Hz, 2H), 1.88-1.75 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.47, 159.75, 146.32, 137.91, 129.56, 129.00, 124.24, 119.84, 118.13, 112.97, 111.29, 74.15, 55.25, 38.11, 37.20, 21.91.

(*R*)-5-hydroxy-5-(4-methoxyphenyl)-*N*-phenylpentanamide (2g)




White solid, $[\alpha]_D^{20} = 76.0$ ($c = 0.2$, CHCl_3), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel AS-H column, 220 nm, 20 °C, *n*-hexane: *i*-PrOH = 90:10; flow 1.0 mL/min; t_R (major) = 40.2 min, t_R (minor) = 60.6 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 8.06 (s, 1H), 7.47 (d, $J = 7.7$ Hz, 2H), 7.28- 7.16 (m, 4H), 7.05 (t, $J = 7.4$ Hz, 1H), 6.87-6.75 (m, 2H), 4.58 (t, $J = 5.8$ Hz, 1H), 3.74 (s, 3H), 3.20 (s, 1H), 2.33-2.30 (m, 2H), 1.86-1.60 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.92, 158.92, 138.07, 136.75, 128.93, 127.11, 124.19, 120.00, 113.81, 73.71, 55.30, 38.12, 37.10, 22.06.

(*R*)-5-(4-fluorophenyl)-5-hydroxy-N-phenylpentanamide (2h)



White solid, $[\alpha]_D^{20} = 25.1$ ($c = 1.0$, CHCl_3), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel AD-H column, 220 nm, 20 °C, *n*-hexane: *i*-PrOH = 85:15; flow 0.5 mL/min; t_R (major) = 21.8 min, t_R (minor) = 20.3 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.68 (s, 1H), 7.48 (d, $J = 7.8$ Hz, 2H), 7.32-7.27 (m, 3H), 7.09 (t, $J = 7.4$ Hz, 1H), 6.99 (t, $J = 8.7$ Hz, 2H), 4.68 (t, $J = 5.6$ Hz, 1H), 2.96 (s, 1H), 2.38 (t, $J = 6.5$ Hz, 2H), 1.90-1.70 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.52, 162.12 (d, $J = 245.3$ Hz), 140.34 (d, $J = 3.1$ Hz), 137.86, 129.01, 127.43 (d, $J = 8.0$ Hz), 124.33, 119.89, 115.27 (d, $J = 21.3$ Hz), 73.48, 38.31, 37.06, 21.78.


(*R*)-5-(4-chlorophenyl)-5-hydroxy-N-phenylpentanamide (2i)



White solid, $[\alpha]_D^{20} = 46.4$ ($c = 0.25$, CHCl_3), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel AS-H column, 220 nm, 20 °C, *n*-hexane: *i*-PrOH = 95:5; flow 1.0 mL/min; t_R (major) = 72.5 min, t_R (minor) = 80.9 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.42 (d, $J = 7.8$ Hz, 2H), 7.37 (s, 1H), 7.30-7.20 (m, 6H), 7.03 (t, $J = 7.4$ Hz, 1H), 4.64 (t, $J = 5.7$ Hz, 1H), 2.61 (s, 1H), 2.34 (t, $J = 6.6$ Hz, 2H), 1.83-1.65 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.22,


142.98, 137.73, 133.10, 128.99, 128.57, 127.14, 124.30, 119.76, 73.42, 38.19, 37.01, 21.56.

(R)-5-hydroxy-5-(naphthalen-2-yl)-N-phenylpentanamide (2j)




White solid, $[\alpha]_D^{20} = 24.4$ ($c = 0.8$, CHCl_3), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel AS-H column, 220 nm, 20°C, *n*-hexane: *i*-PrOH = 95:5; flow 1.0 mL/min; t_R (major) = 29.4 min, t_R (minor) = 34.3 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.85-7.76 (m, 4H), 7.52-7.42 (m, 5H), 7.39 (s, 1H), 7.29 (t, $J = 7.9$ Hz, 4H), 7.09 (t, $J = 7.4$ Hz, 1H), 4.92-4.86 (m, 1H), 2.56 (s, 1H), 2.41 (t, $J = 6.7$ Hz, 2H), 1.97-1.80 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.27, 141.87, 137.85, 133.26, 132.98, 129.02, 128.40, 127.97, 127.71, 126.23, 125.90, 124.51, 124.26, 123.97, 119.78, 74.41, 38.02, 37.25, 21.87.

(R)-5-hydroxy-N-phenyl-5-(thiophen-2-yl)pentanamide (2k)



White solid, $[\alpha]_D^{20} = 12.6$ ($c = 0.9$, CHCl_3), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel OD-H column, 254 nm, 20°C, *n*-hexane: *i*-PrOH = 90:10; flow 1.0 mL/min; t_R (major) = 37.7 min, t_R (minor) = 34.8 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.50 (d, $J = 7.8$ Hz, 2H), 7.34 (s, 1H), 7.33-7.29 (m, 2H), 7.26-7.24 (m, 1H), 7.10 (t, $J = 7.4$ Hz, 1H), 6.98-6.95 (m, 2H), 5.03-4.95 (m, 1H), 2.54 (d, $J = 3.8$ Hz, 1H), 2.44 (t, $J = 6.9$ Hz, 2H), 2.04-1.77 (m, 4H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.23, 148.49, 137.83, 129.03, 126.73, 124.60, 124.31, 123.74, 119.84, 70.03, 38.40, 37.06, 21.72.


(R)-5-cyclohexyl-5-hydroxy-N-phenylpentanamide (2l)



White solid, $[\alpha]_D^{20} = 1.4$ ($c = 1.6$, CHCl_3), >99% conversion, 77% ee. The enantiomeric excess was determined by HPLC on Chiracel OD-H column, 254 nm, 20


$^{\circ}\text{C}$, *n*-hexane: *i*-PrOH = 95:5; flow 0.7 mL/min; t_{R} (major) = 42.4 min, t_{R} (minor) = 47.1 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.58-7.49 (m, 3H), 7.32 (t, J = 7.9 Hz, 2H), 7.10 (t, J = 7.4 Hz, 1H), 3.41 (s, 1H), 2.45-2.41 (m, 2H), 1.94-1.80 (m, 3H), 1.80-1.73 (m, 3H), 1.67-1.50 (m, 3H), 1.38-0.96 (m, 7H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.61, 138.02, 128.99, 124.16, 119.80, 76.05, 43.79, 37.41, 32.96, 29.17, 27.86, 26.50, 26.30, 26.15, 22.15.

(*S*)-2-hydroxy-N,2-diphenylacetamide (2m)




White solid, $[\alpha]_{\text{D}}^{20} = 17.8$ ($c = 0.9$, acetone), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel OJ-H column, 220 nm, 20°C , *n*-hexane: *i*-PrOH = 85:15; flow 1.0 mL/min; t_{R} (major) = 16.0 min, t_{R} (minor) = 14.1 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 8.16 (s, 1H), 7.52 (d, J = 7.8 Hz, 2H), 7.47 (d, J = 7.6 Hz, 2H), 7.43 – 7.35 (m, 3H), 7.31 (t, J = 7.9 Hz, 2H), 7.12 (t, J = 7.4 Hz, 1H), 5.17 (d, J = 2.9 Hz, 1H), 3.50 (d, J = 3.2 Hz, 1H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 170.04, 139.00, 137.05, 129.09, 129.00, 128.91, 126.90, 124.75, 119.82, 74.67.

(*R*)-3-hydroxy-N,3-diphenylpropanamide (2n)



White solid, $[\alpha]_{\text{D}}^{20} = 8.8$ ($c = 0.5$, MeOH), 23% conversion, 90% ee. The enantiomeric excess was determined by HPLC on Chiracel OD-H column, 254 nm, 20°C , *n*-hexane: *i*-PrOH = 95:5; flow 0.5 mL/min; t_{R} (major) = 85.9 min, t_{R} (minor) = 82.5 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 7.76 (s, 1H), 7.50 (d, J = 7.6 Hz, 2H), 7.40-7.34 (m, 7H), 7.13 (t, J = 7.4 Hz, 1H), 5.22 (d, J = 9.4 Hz, 1H), 3.58 (d, J = 2.8 Hz, 1H), 2.84-2.69 (m, 2H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 169.80, 142.72, 137.42, 129.05, 128.71, 127.99, 125.58, 124.60, 120.09, 71.04, 46.02.



(*R*)-4-hydroxy-N,4-diphenylbutanamide (2o)





White solid, $[\alpha]_{\text{D}}^{20} = 61.5$ ($c = 1.0$, CHCl_3), >99% conversion, >99% ee. The enantiomeric excess was determined by HPLC on Chiracel AD-H column, 220 nm, 20 °C, *n*-hexane: *i*-PrOH = 90:10; flow 0.5 mL/min; t_{R} (major) = 33.7 min, t_{R} (minor) = 30.0 min. ^1H NMR (400 MHz, Chloroform-*d*) δ 8.01 (s, 1H), 7.46 (d, $J = 7.7$ Hz, 2H), 7.31 (d, $J = 4.4$ Hz, 4H), 7.29-7.22 (m, 3H), 7.08 (t, $J = 7.4$ Hz, 1H), 4.76 (s, 1H), 3.81 (s, 1H), 2.47-2.43 (m, 2H), 2.10-2.04 (m, 2H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 171.90, 144.17, 137.80, 129.02, 128.53, 127.60, 125.75, 124.41, 120.00, 73.60, 34.20, 33.96.

4. NMR spectra of substrate compounds



5-oxo-N,5-diphenylpentanamide (1a)





5-oxo-N-phenyl-5-(o-tolyl)pentanamide (1b)





5-oxo-N-phenyl-5-(m-tolyl)pentanamide (1c)





5-oxo-N-phenyl-5-(p-tolyl)pentanamide (1d)





5-(2-methoxyphenyl)-5-oxo-N-phenylpentanamide (1e)





5-(3-methoxyphenyl)-5-oxo-N-phenylpentanamide (1f)





5-(4-methoxyphenyl)-5-oxo-N-phenylpentanamide (1g)





5-(4-fluorophenyl)-5-oxo-N-phenylpentanamide (1h)





5-(4-chlorophenyl)-5-oxo-N-phenylpentanamide (1i)





5-(naphthalen-2-yl)-5-oxo-N-phenylpentanamide (1j)





5-oxo-N-phenyl-5-(thiophen-2-yl)pentanamide (1k)





5-cyclohexyl-5-hydroxy-N-phenylpentanamide (1l)





2-oxo-N,2-diphenylacetamide (1m)



3-oxo-N,3-diphenylpropanamide (1n)




4-oxo-N,4-diphenylbutanamide (1o)





5. NMR spectra of products



(*R*)-5-hydroxy-N,5-diphenylpentanamide (2a)





(R)-5-hydroxy-N-phenyl-5-(o-tolyl)pentanamide (2b)





(R)-5-hydroxy-N-phenyl-5-(m-tolyl)pentanamide (2c)





(R)-5-hydroxy-N-phenyl-5-(p-tolyl)pentanamide (2d)





(R)-5-hydroxy-5-(2-methoxyphenyl)-N-phenylpentanamide (2e)





(R)-5-hydroxy-5-(3-methoxyphenyl)-N-phenylpentanamide (2f)





(R)-5-hydroxy-5-(4-methoxyphenyl)-N-phenylpentanamide (2g)





(R)-5-(4-fluorophenyl)-5-hydroxy-N-phenylpentanamide (2h)





(R)-5-(4-chlorophenyl)-5-hydroxy-N-phenylpentanamide (2i)





(R)-5-hydroxy-5-(naphthalen-2-yl)-N-phenylpentanamide (2j)





(R)-5-hydroxy-N-phenyl-5-(thiophen-2-yl)pentanamide (2k)





(R)-5-cyclohexyl-5-hydroxy-N-phenylpentanamide (2l)





(S)-2-hydroxy-N,2-diphenylacetamide (2m)



(R)-3-hydroxy-N,3-diphenylpropanamide (2n)



(R)-4-hydroxy-N,4-diphenylbutanamide (2o)




6. HPLC spectra

(R)-5-hydroxy-N,5-diphenylpentanamide (2a)

Data File E:\DATA\YXG\HY-2017-9-6\LWD-2-179-KOH 2017-09-06 15-18-34\001-0201.D
Sample Name: RAC

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 1
Injection Date  : 9/6/2017 3:50:06 PM          Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\YXG\HY-2017-9-6\LWD-2-179-KOH 2017-09-06 15-18-34\VWD-AD (1-2)-85
                                           -15-1.0-5UL-220NM-60MIN.M
Last changed    : 9/6/2017 4:12:40 PM by SYSTEM
                                           (modified after loading)
Analysis Method : E:\DATA\YXG\HY-2017-9-6\LWD-2-179-KOH 2017-09-06 15-18-34\VWD-AD (1-2)-85
                                           -15-1.0-5UL-220NM-60MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:09:11 AM by SYSTEM
                                           (modified after loading)
Additional Info : Peak(s) manually integrated
VWD1 A, Wavelength=220 nm (E:\DATA\YXG\HY-2017-9-6\LWD-2-179-KOH 2017-09-06 15-18-34\001-0201.D)
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```


Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.308	BV	0.3631	2.85638e4	1198.24341	49.8493
2	13.924	VB	0.4242	2.87365e4	976.92010	50.1507

Totals : 5.73004e4 2175.16351

Data File E:\DATA\YXG\HY-2017-9-6\LWD-2-179-KOH 2017-09-06 15-18-34\006-0701.D
Sample Name: iPrOH

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    7
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 6
Injection Date  : 9/6/2017 5:40:47 PM         Inj       :    1
                                           Inj Volume: 1.000 µl
Acq. Method     : E:\DATA\YXG\HY-2017-9-6\LWD-2-179-KOH 2017-09-06 15-18-34\VWD-AD (1-2)-85
                  -15-1.0-5UL-220NM-60MIN.M
Last changed    : 9/6/2017 4:44:52 PM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-2017-9-6\LWD-2-179-KOH 2017-09-06 15-18-34\VWD-AD (1-2)-85
                  -15-1.0-5UL-220NM-60MIN.M (Sequence Method)
Last changed    : 3/4/2018 11:16:07 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



```
=====
                          Area Percent Report
=====
```

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.760	BB	0.3813	1.18646e4	468.67468	100.0000

Totals : 1.18646e4 468.67468


```
=====
                          *** End of Report ***
=====
```

(R)-5-hydroxy-N-phenyl-5-(o-tolyl)pentanamide (2b)

Data File E:\DATA\YXG\HY-4-OME\HY-4-OME 2018-03-21 08-47-13\003-0201.D
Sample Name: 2-me-rac

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 3
Injection Date  : 3/21/2018 9:30:11 AM        Inj       :    1
                                           Inj Volume: 3.000 µl

Acq. Method     : E:\DATA\YXG\HY-4-OME\HY-4-OME 2018-03-21 08-47-13\VWD-AD(1-2)-90-10-1ML-
3UL-210NM-40MIN.M
Last changed    : 3/21/2018 8:47:13 AM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-4-OME\HY-4-OME 2018-03-21 08-47-13\VWD-AD(1-2)-90-10-1ML-
3UL-210NM-40MIN.M (Sequence Method)
Last changed    : 3/21/2018 2:06:11 PM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	21.652	VV	0.5986	9970.05957	255.88293	49.5089
2	22.956	VB	0.6406	1.01678e4	242.79451	50.4911

Totals : 2.01379e4 498.67744

*** End of Report ***


Data File E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\041-0201.D
Sample Name: HY-2-Me

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 41
Injection Date  : 3/6/2018 8:42:49 AM          Inj       :    1
                                           Inj Volume: 3.000 µl

Acq. Method     : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AD(1-2)-90-
                  10-1ML-3UL-210NM-40MIN.M
Last changed    : 3/6/2018 8:31:13 AM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AD(1-2)-90-
                  10-1ML-3UL-210NM-40MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:42:43 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated

```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs

```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	21.288	MF	0.6874	3.51288e4	851.66882	97.3342
2	22.625	FM	0.6569	982.10657	24.40915	2.6658

Totals : 3.60909e4 876.07797


*** End of Report ***

(R)-5-hydroxy-N-phenyl-5-(m-tolyl)pentanamide (2c)

Data File E:\DATA\HY\HY-2017-12-06\HY-2017-12-06 2017-12-06 22-26-24\001-0201.D

Sample Name: HY-2017-12-06-3Me-RAC

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 1
Injection Date  : 12/6/2017 10:48:07 PM       Inj       :    1
                                           Inj Volume: 1.000 µl
Acq. Method     : E:\DATA\HY\HY-2017-12-06\HY-2017-12-06 2017-12-06 22-26-24\VWD-AD(1-2)-
                  85-15-1.0-1UL-220NM-40MIN.M
Last changed    : 12/6/2017 10:26:25 PM by SYSTEM
Analysis Method : E:\DATA\HY\HY-2017-12-06\HY-2017-12-06 2017-12-06 22-26-24\VWD-AD(1-2)-
                  85-15-1.0-1UL-220NM-40MIN.M (Sequence Method)
Last changed    : 3/4/2018 11:30:18 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.754	BB	0.2921	1834.05481	95.48607	50.0238
2	13.807	BB	0.3945	1832.30615	70.90994	49.9762

Totals : 3666.36096 166.39601

*** End of Report ***

Data File E:\DATA\HY\HY-2017-12-06\HY-2017-12-06 2017-12-06 22-26-24\002-0301.D
Sample Name: HY-2017-12-06-3Me-EE

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 2
Injection Date  : 12/6/2017 11:28:48 PM       Inj       :    1
                                           Inj Volume: 1.000 µl
Acq. Method     : E:\DATA\HY\HY-2017-12-06\HY-2017-12-06 2017-12-06 22-26-24\VWD-AD(1-2)-
85-15-1.0-1UL-220NM-40MIN.M
Last changed    : 12/6/2017 10:26:25 PM by SYSTEM
Analysis Method : E:\DATA\HY\HY-2017-12-06\HY-2017-12-06 2017-12-06 22-26-24\VWD-AD(1-2)-
85-15-1.0-1UL-220NM-40MIN.M (Sequence Method)
Last changed    : 3/4/2018 11:32:04 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.746	BB	0.3931	6691.59375	259.28629	100.0000

Totals : 6691.59375 259.28629


=====
*** End of Report ***

(R)-5-hydroxy-N-phenyl-5-(p-tolyl)pentanamide (2d)

Data File E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 11-02-48\032-0101.D

Sample Name: HY-4-Me-RACE

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 32
Injection Date  : 3/5/2018 11:03:34 AM        Inj       :    1
                                           Inj Volume: 3.000 µl
Acq. Method     : E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 11-02-48\DAD-AS
                  (1-6)-90-10-1ML-3UL-220NM-60MIN.M
Last changed    : 3/5/2018 11:26:15 AM by SYSTEM
                  (modified after loading)
Analysis Method : E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 11-02-48\DAD-AS
                  (1-6)-90-10-1ML-3UL-220NM-60MIN.M (Sequence Method)
Last changed    : 3/19/2018 8:41:28 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	20.050	BV	0.9438	1.39227e4	225.03658	49.3087
2	22.403	VB	1.1303	1.43130e4	191.87627	50.6913

Totals : 2.82357e4 416.91284

Data File E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\042-0301.D
Sample Name: HY-4-Me

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 42
Injection Date  : 3/6/2018 9:23:38 AM          Inj       :    1
                                           Inj Volume: 5.000 µl

Acq. Method     : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AS(1-6)-90-
                  10-1ML-3UL-220NM-40MIN.M
Last changed    : 3/6/2018 8:31:13 AM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AS(1-6)-90-
                  10-1ML-3UL-220NM-40MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:45:45 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	19.845	BB	0.9927	2.02177e4	309.24850	100.0000

Totals : 2.02177e4 309.24850


=====
*** End of Report ***

(R)-5-hydroxy-5-(2-methoxyphenyl)-N-phenylpentanamide (2e)

Data File E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 12-01-44\034-0201.D

Sample Name: HY-2-OMe RACE

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 34
Injection Date  : 3/5/2018 1:38:28 PM          Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 12-01-44\VWD-AD
                  (1-2)-90-10-1.0ML-3UL-220NM-60MIN.M
Last changed    : 3/5/2018 2:37:01 PM by SYSTEM
                  (modified after loading)
Analysis Method : E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 12-01-44\VWD-AD
                  (1-2)-90-10-1.0ML-3UL-220NM-60MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:00:17 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	43.653	BB	1.1906	1.65428e4	211.93987	49.8962
2	54.960	MM	1.6947	1.66116e4	163.36815	50.1038


Totals : 3.31544e4 375.30801

Data File E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\044-0501.D
Sample Name: HY-2-OMe

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    5
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 44
Injection Date  : 3/6/2018 11:45:21 AM        Inj       :    1
                                           Inj Volume: 5.000 µl

Acq. Method     : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AD(1-2)-90-
                  10-1ML-5UL-220NM-75MIN.M
Last changed    : 3/6/2018 8:31:13 AM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AD(1-2)-90-
                  10-1ML-5UL-220NM-75MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:50:59 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	44.176	BB	1.2124	4331.05273	54.54423	5.8762
2	56.068	BB	1.6010	6.93737e4	648.03125	94.1238

Totals : 7.37048e4 702.57548


*** End of Report ***

(R)-5-hydroxy-5-(3-methoxyphenyl)-N-phenylpentanamide (2f)

Data File E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 12-01-44\035-0301.D
Sample Name: HY-3-OMe-RACE

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 35
Injection Date  : 3/5/2018 2:44:16 PM          Inj       :    1
                                           Inj Volume: 5.000 µl

Acq. Method     : E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 12-01-44\VWD-AD
                  (1-2)-90-10-1.0ML-3UL-220NM-60MIN.M
Last changed    : 3/5/2018 3:33:51 PM by SYSTEM
                  (modified after loading)
Analysis Method : E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 12-01-44\VWD-AD
                  (1-2)-90-10-1.0ML-3UL-220NM-60MIN.M (Sequence Method)
Last changed    : 3/8/2018 9:57:50 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
=====
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	34.630	BB	0.9675	4264.64502	67.01236	50.0685
2	42.505	BB	1.2125	4252.97168	53.26817	49.9315


Totals : 8517.61670 120.28053

Data File E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\045-0601.D
Sample Name: HY-3-OMe

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    6
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 45
Injection Date  : 3/6/2018 1:01:11 PM          Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AD(1-2)-90-
                                           10-1ML-5UL-220NM-60MIN.M
Last changed    : 3/6/2018 8:31:13 AM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AD(1-2)-90-
                                           10-1ML-5UL-220NM-60MIN.M (Sequence Method)
Last changed    : 3/15/2018 3:30:54 PM by SYSTEM
                                           (modified after loading)
Additional Info : Peak(s) manually integrated

```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	35.090	BB	0.9146	343.49542	5.28935	0.8160
2	43.451	BB	1.2260	4.17513e4	492.03580	99.1840


Totals : 4.20948e4 497.32515

*** End of Report ***

(R)-5-hydroxy-5-(4-methoxyphenyl)-N-phenylpentanamide (2g)

Data File E:\DATA\SC...21-4-OMe\HY-20180321-4-OMe 2018-03-21 12-14-05\HY-20180321-4-OMe1.D
Sample Name: HY-20180321-4-OMe-RAC

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   23
Injection Date  : 3/21/2018 12:32:15 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\ZHANG-HY-20180321-4-OMe\HY-20180321-4-OMe 2018-03-21 12-14-05\SC
                  -1-ASH-90-10-DAD--90MIN-1ML.M
Last changed    : 3/21/2018 12:14:05 PM by SYSTEM
Analysis Method : E:\DATA\SC\ZHANG-HY-20180321-4-OMe\HY-20180321-4-OMe 2018-03-21 12-14-05\SC
                  -1-ASH-90-10-DAD--90MIN-1ML.M (Sequence Method)
Last changed    : 3/21/2018 3:18:01 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```


Signal 1: DAD1 B, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	40.234	MM	2.3063	6865.19482	49.61203	49.9542
2	60.638	MM	4.5591	6877.79639	25.14311	50.0458

Totals : 1.37430e4 74.75514

Data File E:\DATA\SC...21-4-OMe\HY-20180321-4-OMe 2018-03-21 12-14-05\HY-20180321-4-OMe2.D
Sample Name: HY-20180321-4-OMe-OPT

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                      Location  :   24
Injection Date  : 3/21/2018 2:03:46 PM        Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\ZHANG-HY-20180321-4-OMe\HY-20180321-4-OMe 2018-03-21 12-14-05\SC
                  -1-ASH-90-10-DAD--90MIN-1ML.M
Last changed    : 3/21/2018 12:14:05 PM by SYSTEM
Analysis Method : E:\DATA\SC\ZHANG-HY-20180321-4-OMe\HY-20180321-4-OMe 2018-03-21 12-14-05\SC
                  -1-ASH-90-10-DAD--90MIN-1ML.M (Sequence Method)
Last changed    : 3/21/2018 3:34:48 PM by SYSTEM
                  (modified after loading)
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 B, Sig=254,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	38.057	BB	1.8393	2.68096e4	180.97954	100.0000

Totals : 2.68096e4 180.97954

(R)-5-(4-fluorophenyl)-5-hydroxy-N-phenylpentanamide (2h)

Data File E:\DATA\YXG\HY-2017-9-25\HY-2017-9-25 2017-09-25 18-54-05\003-0201.D
Sample Name: HY-2017-9-25-4-F-RAC-3

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 3
Injection Date  : 9/25/2017 7:05:33 PM        Inj       :    1
                                           Inj Volume: 1.000 µl
Acq. Method     : E:\DATA\YXG\HY-2017-9-25\HY-2017-9-25 2017-09-25 18-54-05\VWD-AD (1-6)-85
                  -15-0.5-1UL-220NM-60MIN.M
Last changed    : 9/25/2017 7:51:08 PM by SYSTEM
                  (modified after loading)
Analysis Method : E:\DATA\YXG\HY-2017-9-25\HY-2017-9-25 2017-09-25 18-54-05\VWD-AD (1-6)-85
                  -15-0.5-1UL-220NM-60MIN.M (Sequence Method)
Last changed    : 3/4/2018 11:36:18 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
=====
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	20.294	BV	0.4576	7041.72607	232.35959	49.6944
2	21.823	VB	0.4910	7128.32568	219.42799	50.3056

Totals : 1.41701e4 451.78758


Data File E:\DATA\HY\HY-2017-12-06\HY-2017-12-06 2017-12-06 22-26-24\003-0501.D
Sample Name: HY-2017-12-06-4F-EE

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    5
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 3
Injection Date  : 12/7/2017 12:20:22 AM       Inj       :    1
                                           Inj Volume: 1.000 µl

Acq. Method     : E:\DATA\HY\HY-2017-12-06\HY-2017-12-06 2017-12-06 22-26-24\VWD-AD(1-2)-
                  85-15-0.5-1UL-220NM-40MIN.M
Last changed    : 12/6/2017 10:26:25 PM by SYSTEM
Analysis Method : E:\DATA\HY\HY-2017-12-06\HY-2017-12-06 2017-12-06 22-26-24\VWD-AD(1-2)-
                  85-15-0.5-1UL-220NM-40MIN.M (Sequence Method)
Last changed    : 3/4/2018 11:33:34 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated

```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs

```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	21.460	BB	0.4851	5004.68115	155.67137	100.0000

Totals : 5004.68115 155.67137


*** End of Report ***

(R)-5-(4-chlorophenyl)-5-hydroxy-N-phenylpentanamide (2i)

Data File E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 12-01-44\033-0101.D
Sample Name: HY-4-C1-RACE

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 33
Injection Date  : 3/5/2018 12:02:33 PM        Inj       :    1
                                           Inj Volume: 6.000 µl

Acq. Method     : E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 12-01-44\DAD-AS
                  (1-6)-95-5-1ML-6UL-220NM-60MIN.M
Last changed    : 3/5/2018 1:27:26 PM by SYSTEM
                  (modified after loading)
Analysis Method : E:\DATA\YXG\HY-20180305-RACE\HY-20180305-RACE 2018-03-05 12-01-44\DAD-AS
                  (1-6)-95-5-1ML-6UL-220NM-60MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:02:11 AM by SYSTEM
                  (modified after loading)
Additional Info  : Peak(s) manually integrated
```



Area Percent Report

```
=====
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	72.654	MF	3.8065	2.22891e4	97.59178	49.8239
2	80.959	FM	4.4414	2.24466e4	84.23253	50.1761

Totals : 4.47357e4 181.82431


Data File E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\043-0401.D
Sample Name: HY-4-C1

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    4
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 43
Injection Date  : 3/6/2018 10:04:32 AM         Inj       :    1
                                           Inj Volume: 5.000 µl

Acq. Method     : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AS(1-6)-95-5
                  -1ML-5UL-220NM-100MIN.M
Last changed    : 3/6/2018 8:31:13 AM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-20180306\HY-20180306 2018-03-06 08-31-13\VWD-AS(1-6)-95-5
                  -1ML-5UL-220NM-100MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:48:06 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated

```



```

=====
                        Area Percent Report
=====

```

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs

```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	72.344	BB	3.1905	4.47401e4	170.10446	100.0000

Totals : 4.47401e4 170.10446

```

=====
                        *** End of Report ***


```

(R)-5-hydroxy-5-(naphthalen-2-yl)-N-phenylpentanamide (2j)

Data File E:\DATA\YXG\HY-20180226RACE\HY-20180226-RACE 2018-02-26 13-44-52\001-0201.D
Sample Name: HY-NAI-RACE

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 1
Injection Date  : 2/26/2018 1:56:26 PM         Inj       :    1
                                           Inj Volume: 5.000 µl

Acq. Method     : E:\DATA\YXG\HY-20180226RACE\HY-20180226-RACE 2018-02-26 13-44-52\VWD-AS(
                  1-6)-95-5-1.0ML-3UL-210NM-60MIN.M
Last changed    : 2/26/2018 1:44:52 PM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-20180226RACE\HY-20180226-RACE 2018-02-26 13-44-52\VWD-AS(
                  1-6)-95-5-1.0ML-3UL-210NM-60MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:14:33 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	29.779	MF	1.5989	5.96365e4	621.65820	50.8960
2	34.015	FM	1.9140	5.75367e4	501.00873	49.1040

Totals : 1.17173e5 1122.66693


```
=====
*** End of Report ***
```

Data File E:\DATA\YXG\HY-20180226RACE\HY-20180226-RACE 2018-02-26 15-00-53\011-0201.D
Sample Name: HY-NAI

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 11
Injection Date  : 2/26/2018 4:03:18 PM        Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\YXG\HY-20180226RACE\HY-20180226-RACE 2018-02-26 15-00-53\VWD-AS(
                  1-6)-95-5-1.0ML-3UL-210NM-60MIN.M
Last changed    : 2/26/2018 3:00:53 PM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-20180226RACE\HY-20180226-RACE 2018-02-26 15-00-53\VWD-AS(
                  1-6)-95-5-1.0ML-3UL-210NM-60MIN.M (Sequence Method)
Last changed    : 3/4/2018 10:59:10 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====

```



```

=====
                          Area Percent Report
=====

```

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs

```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	29.396	VB	1.5956	2.15094e5	2049.17432	99.6990
2	34.302	BB	1.1069	649.41217	8.38173	0.3010

Totals : 2.15743e5 2057.55604

```


=====
*** End of Report ***

```

(R)-5-hydroxy-N-phenyl-5-(thiophen-2-yl)pentanamide (2k)

Data File E:\DATA\HYI\HYI-2-154-0.5ML\HYI-2-153-154 2017-12-20 14-43-53\001-0201.D
Sample Name: HY-SAIFEN-RAC

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-DAD                Location  : Vial 1
Injection Date  : 12/20/2017 2:56:55 PM       Inj       :    1
                                           Inj Volume: 1.000 µl
Acq. Method     : E:\DATA\HYI\HYI-2-154-0.5ML\HYI-2-153-154 2017-12-20 14-43-53\
DAD-0D(1-2)-90-10-1ML-1UL-ALL-1H.M
Last changed    : 12/20/2017 3:36:51 PM by SYSTEM
                  (modified after loading)
Analysis Method : E:\DATA\HYI\HYI-2-154-0.5ML\HYI-2-153-154 2017-12-20 14-43-53\
DAD-0D(1-2)-90-10-1ML-1UL-ALL-1H.M (Sequence Method)
Last changed    : 3/8/2018 10:18:08 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
=====
```

Signal 1: DAD1 B, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	34.789	MF	1.7133	8077.33350	78.57515	49.5213
2	38.595	FM	1.9492	8233.48340	70.40156	50.4787


Totals : 1.63108e4 148.97671

Data File E:\DATA\YXG\YXG-894-2\HY-BUSHUJU20180208 2018-02-08 13-18-12\022-0301.D
Sample Name: HY-saifen

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260HPLC-DAD                Location  : Vial 22
Injection Date  : 2/8/2018 2:51:07 PM          Inj       :    1
                                           Inj Volume: 3.000 µl
Acq. Method     : E:\DATA\YXG\YXG-894-2\HY-BUSHUJU20180208 2018-02-08 13-18-12\DAD-OD (1-2)
                                           -90-10--1ML-210-230NM-60MIN.M
Last changed    : 2/8/2018 1:18:12 PM by SYSTEM
Analysis Method : E:\DATA\YXG\YXG-894-2\HY-BUSHUJU20180208 2018-02-08 13-18-12\DAD-OD (1-2)
                                           -90-10--1ML-210-230NM-60MIN.M (Sequence Method)
Last changed    : 3/4/2018 12:37:40 PM by SYSTEM
                                           (modified after loading)
Additional Info : Peak(s) manually integrated

```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs

```

Signal 1: DAD1 B, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	34.830	MM	0.5646	5.49173	1.62112e-1	0.0173
2	37.743	BB	1.7114	3.17273e4	270.70624	99.9827


Totals : 3.17328e4 270.86835

*** End of Report ***

(R)-5-cyclohexyl-5-hydroxy-N-phenylpentanamide (2l)

Data File E:\DATA\YXG\HY-HUANJIIJI-RACE\HY-HUANJIIJI-RACE 2018-02-27 15-51-59\032-0201.D
Sample Name: HY-HUANJIIJI-RACE

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-DAD                Location  : Vial 32
Injection Date  : 2/27/2018 4:04:00 PM         Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\YXG\HY-HUANJIIJI-RACE\HY-HUANJIIJI-RACE 2018-02-27 15-51-59\DAD-0D
                  (1-2)-95-5-0.7ML-210-230NM-60MIN.M
Last changed    : 2/27/2018 4:56:09 PM by SYSTEM
                  (modified after loading)
Analysis Method : E:\DATA\YXG\HY-HUANJIIJI-RACE\HY-HUANJIIJI-RACE 2018-02-27 15-51-59\DAD-0D
                  (1-2)-95-5-0.7ML-210-230NM-60MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:23:23 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 B, Sig=254.4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	41.873	MF	1.9117	1.22385e4	106.70069	48.8931
2	45.730	FM	2.1120	1.27926e4	100.95264	51.1069

Totals : 2.50312e4 207.65333


Data File E:\DATA\YXG\HY-HUANJIJI-RACE\HY-HUANJIJI-RACE 2018-02-27 15-51-59\033-0301.D
Sample Name: HY-HUANJIJI

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260HPLC-DAD                Location  : Vial 33
Injection Date  : 2/27/2018 5:04:56 PM        Inj       :    1
                                           Inj Volume: 5.000 µl

Acq. Method     : E:\DATA\YXG\HY-HUANJIJI-RACE\HY-HUANJIJI-RACE 2018-02-27 15-51-59\DAD-OD
                  (1-2)-95-5-0.7ML-210-230NM-60MIN.M
Last changed    : 2/27/2018 4:56:09 PM by SYSTEM
Analysis Method : E:\DATA\YXG\HY-HUANJIJI-RACE\HY-HUANJIJI-RACE 2018-02-27 15-51-59\DAD-OD
                  (1-2)-95-5-0.7ML-210-230NM-60MIN.M (Sequence Method)
Last changed    : 3/8/2018 10:26:20 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated

```



=====
Area Percent Report
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs

```

Signal 1: DAD1 B, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	42.413	MF	1.9221	3.55451e4	308.21945	88.2708
2	47.135	FM	2.0490	4723.13672	38.41894	11.7292

Totals : 4.02683e4 346.63839


=====
*** End of Report ***

(S)-2-hydroxy-N,2-diphenylacetamide (2m)

Data File E:\DATA\HY\HY-2017-9-27\SUB-20170926 2017-09-27 09-42-12\005-0701.D
Sample Name: HY-AERFA-RAC

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    7
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 5
Injection Date  : 9/27/2017 12:50:58 PM        Inj       :    1
                                           Inj Volume: 1.000 µl

Acq. Method     : E:\DATA\HY\HY-2017-9-27\SUB-20170926 2017-09-27 09-42-12\VWD-0J(1-6)-85-
                  15-1ML-1UL-220NM-40MIN.M
Last changed    : 9/27/2017 1:23:09 PM by SYSTEM
                  (modified after loading)
Analysis Method : E:\DATA\HY\HY-2017-9-27\SUB-20170926 2017-09-27 09-42-12\VWD-0J(1-6)-85-
                  15-1ML-1UL-220NM-40MIN.M (Sequence Method)
Last changed    : 3/4/2018 11:41:04 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
```



Area Percent Report

```
=====
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.677	BB	0.4301	3683.54932	127.85548	49.4296
2	17.473	BB	0.4279	3768.55908	132.85428	50.5704

Totals : 7452.10840 260.70976


Data File E:\DATA\YXG\YXG-894-2\HY-BUSHUJU20180208 2018-02-08 13-18-12\023-0401.D
Sample Name: HY-a-chanwu

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    4
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 23
Injection Date  : 2/8/2018 3:52:08 PM          Inj       :    1
                                           Inj Volume: 1.000 µl

Acq. Method     : E:\DATA\YXG\YXG-894-2\HY-BUSHUJU20180208 2018-02-08 13-18-12\VWD-0J(1-6)
                  -85-15-1ML-1UL-220NM-40MIN.M
Last changed    : 2/8/2018 1:18:12 PM by SYSTEM
Analysis Method : E:\DATA\YXG\YXG-894-2\HY-BUSHUJU20180208 2018-02-08 13-18-12\VWD-0J(1-6)
                  -85-15-1ML-1UL-220NM-40MIN.M (Sequence Method)
Last changed    : 3/4/2018 12:55:04 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====

```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution      : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

```

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.114	BB	0.4061	123.46416	4.26015	0.4575
2	16.004	BB	0.6175	2.68627e4	664.73956	99.5425

Totals : 2.69861e4 668.99971


*** End of Report ***

(R)-3-hydroxy-N,3-diphenylpropanamide (2n)

Data File E:\DATA\YCC\YCC-2018-01-17\YCC-222 2018-03-20 12-34-29\031-2201.D
Sample Name: BEITA-RAC

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :   22
Acq. Instrument : 1260HPLC-DAD                Location  : Vial 31
Injection Date  : 3/20/2018 10:03:42 PM       Inj       :    1
                                           Inj Volume: 10.000 µl

Acq. Method     : E:\DATA\YCC\YCC-2018-01-17\YCC-222 2018-03-20 12-34-29\DAD-OD (1-2)-95-5-
                  0.5ML-10UL-100MIN.M
Last changed    : 3/20/2018 8:14:42 PM by SYSTEM
Analysis Method : E:\DATA\YCC\YCC-2018-01-17\YCC-222 2018-03-20 12-34-29\DAD-OD (1-2)-95-5-
                  0.5ML-10UL-100MIN.M (Sequence Method)
Last changed    : 3/21/2018 3:47:55 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
DAD1 B, Sig=254,4 Ref=off (E:\DATA\YCC\YCC-2018-01-17\YCC-222 2018-03-20 12-34-29\031-2201.D)
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 B, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	80.723	MF	3.0053	4.27600e4	237.13538	48.0272
2	86.393	FM	3.7267	4.62729e4	206.94102	51.9728

Totals : 8.90329e4 444.07640

*** End of Report ***


Data File E:\DATA\YCC\YCC-2018-01-17\YCC-222 2018-03-20 12-34-29\032-2301.D
Sample Name: BEITA-EE

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :   23
Acq. Instrument : 1260HPLC-DAD                Location  : Vial 32
Injection Date  : 3/20/2018 11:44:43 PM       Inj       :    1
                                           Inj Volume: 10.000 µl

Acq. Method     : E:\DATA\YCC\YCC-2018-01-17\YCC-222 2018-03-20 12-34-29\
0.5ML-10UL-100MIN.M
Last changed    : 3/20/2018 8:14:42 PM by SYSTEM
Analysis Method : E:\DATA\YCC\YCC-2018-01-17\YCC-222 2018-03-20 12-34-29\
0.5ML-10UL-100MIN.M (Sequence Method)
Last changed    : 3/21/2018 3:52:24 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
=====

```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

```

Signal 1: DAD1 B, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	82.486	BB	1.2306	2323.46973	22.28021	4.8588
2	85.881	BB	2.4519	4.54960e4	247.58150	95.1412


Totals : 4.78194e4 269.86171

*** End of Report ***

(R)-4-hydroxy-N,4-diphenylbutanamide (2o)

Data File E:\DATA\WSW\LWD-2-197-11-12\LWD-2-197-11-12 2017-09-25 11-25-46\003-0201.D
Sample Name: HY-2017-9-25-JIAMA-RAC

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 3
Injection Date  : 9/25/2017 11:44:15 AM        Inj       :    1
                                           Inj Volume: 1.000 µl
Acq. Method     : E:\DATA\WSW\LWD-2-197-11-12\LWD-2-197-11-12 2017-09-25 11-25-46\VWD-AD (1
-6)-90-10-0.5-220NM-40MIN.M
Last changed    : 9/25/2017 11:25:46 AM by SYSTEM
Analysis Method : E:\DATA\WSW\LWD-2-197-11-12\LWD-2-197-11-12 2017-09-25 11-25-46\VWD-AD (1
-6)-90-10-0.5-220NM-40MIN.M (Sequence Method)
Last changed    : 3/4/2018 11:48:26 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



Area Percent Report

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: VWD1 A, Wavelength=220 nm


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	30.032	BB	0.6439	2893.94897	67.54469	50.1456
2	33.719	BBA	0.7499	2877.14575	58.08632	49.8544

Totals : 5771.09473 125.63101

*** End of Report ***

Data File E:\DATA\WSW\LWD-2-197-11-12\LWD-2-197-11-12 2017-09-25 11-25-46\004-0301.D
Sample Name: HY-2017-9-25-JIAMA-EE

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260HPLC-VWD                Location  : Vial 4
Injection Date  : 9/25/2017 12:24:58 PM        Inj       :    1
                                           Inj Volume: 1.000 µl
Acq. Method     : E:\DATA\WSW\LWD-2-197-11-12\LWD-2-197-11-12 2017-09-25 11-25-46\VWD-AD (1
-6)-90-10-0.5-220NM-40MIN.M
Last changed    : 9/25/2017 11:25:46 AM by SYSTEM
Analysis Method : E:\DATA\WSW\LWD-2-197-11-12\LWD-2-197-11-12 2017-09-25 11-25-46\VWD-AD (1
-6)-90-10-0.5-220NM-40MIN.M (Sequence Method)
Last changed    : 3/4/2018 11:51:19 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	33.238	BB	0.7485	7760.06836	155.95757	100.0000

Totals : 7760.06836 155.95757

=====
*** End of Report ***

7. References

- (1) C. Joyanta, P. Susmita, R. Sujit, *J. Am. Chem. Soc.*, 2005, **127**, 6162;
- (2) D. Yang, Y. Long, H. Wang, Z. Zhang, *Org. Lett.*, 2008, **10**, 4723;
- (3) N. C. Mamillapalli, G. Sekar, *Chem. Eur. J.*, 2015, **21**, 18584;
- (4) N. A. Cortez, G. Aguirre, M. Parra-Hake, R. Somanathan, *Tetrahedron: Asymmetric*, 2013, **24**, 1297;
- (5) C. David; B. Juan; K. Donnalld, WO2006017257, 2006;
- (6) C. Liu, Y. Li, C. Li, W. Li, C. Zhou, H. Liu, Z. Bo and Y. Li, *J. Phy. Chem. C*, 2009, **113**, 21970;
- (7) M. Zhao, B. Lu, G. Ding, K. Ren, X. Xie and Z. Zhang, *Org. & Biomol. Chem.*, 2016, **14**, 2723;
- (8) J. Zhuang, C. Wang, F. Xie and W. Zhang, *Tetrahedron*, 2009, **65**, 9797;
- (9) M. Wasa, R. Y. Liu, S. P. Roche and E. N. Jacobsen, *J. Am. Chem. Soc.*, 2014, **136**, 12872.